Bisacodyl, senna OTC laxative safety data requested by June 1999 in FDA proposal.
This article was originally published in The Tan Sheet
Executive Summary
BISACODYL, SENNA OTC LAXATIVE SAFETY DATA REQUESTED BY JUNE 1999 in an FDA proposed rule published in the June 19 Federal Register. As expected, the proposal tentatively reclassifies senna, bisacodyl, cascara sagrada and aloe from Category I (safe and effective) to Category III (further testing needed) in the tentative final monograph for OTC laxatives and reopens the administrative record for data considered necessary to establish the safety of the ingredients.
You may also be interested in...
Cascara Sagrada, Aloe Laxatives, O-9 Contraceptive Are Category II – FDA
Reformulation of all cascara sagrada- and aloe-containing laxatives with approved active ingredients could cost industry up to $17.8 mil., including an estimated relabeling cost of $612,000, FDA states
Cascara Sagrada, Aloe Laxatives, O-9 Contraceptive Are Category II – FDA
Reformulation of all cascara sagrada- and aloe-containing laxatives with approved active ingredients could cost industry up to $17.8 mil., including an estimated relabeling cost of $612,000, FDA states
Cascara Sagrada, Aloe Laxatives, O-9 Contraceptive Are Category II – FDA
Reformulation of all cascara sagrada- and aloe-containing laxatives with approved active ingredients could cost industry up to $17.8 mil., including an estimated relabeling cost of $612,000, FDA states